Friday 6 November 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue: +29.2%
EPS: +178.4%
Free cash flow: +38.9%
Total debt: +1,765.6%

Quarter to September 2026, against a year earlier

253.57 12.11 +5.02%

Follow MRNA

Alert me

Market cap: $96.4B
P/E: 0.0×
Fwd P/E: −26.1×
Dividend yield: —
F-score: 3/9
Altman Z: 2.46
Beneish M: −3.52
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Moderna, Inc. 10-Q filed Aug 1, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed Aug 1, 2025 · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 1, 2025: no material changes, the filing says